Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial

Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial

Abstract Background Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both atherogenesis and ischemia and reperfusion injury (IRI). Sodium-glucose-2 co-transporter inhibitors (SGLT2i) may hypothetically improve microvascular and macrovascular functions via a br...

Full description

Bibliographic Details
Main Authors: Riobaldo M. R. Cintra, Alexandre A. S. Soares, Ikaro Breder, Daniel B. Munhoz, Joaquim Barreto, Sheila T. Kimura-Medorima, Pamela Cavalcante, Renata Zanchetta, Jessica Cunha Breder, Camila Moreira, Vitor W. Virginio, Isabella Bonilha, Jose Carlos Lima-Junior, Otavio R. Coelho-Filho, Vaneza L. W. Wolf, Gil Guerra-Junior, Daniela C. Oliveira, Rodrigo Haeitmann, Vicente H. R. Fernandes, Wilson Nadruz, Fernando R. P. Chaves, Carlos E. L. Arieta, Thiago Quinaglia, Andrei C. Sposito, ADDENDA-BHS2 trial investigators
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Diabetes
Endothelial function
SGLT2i
Dapagliflozin
Glibenclamide
Online Access:http://link.springer.com/article/10.1186/s13098-019-0457-3

Internet

http://link.springer.com/article/10.1186/s13098-019-0457-3

Similar Items